AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.

@inproceedings{Antonarakis2016ARV7AE,
  title={AR-V7 and efficacy of abiraterone (Abi) and enzalutamide (Enza) in castration-resistant prostate cancer (CRPC): Expanded analysis of the Johns Hopkins cohort.},
  author={Emmanuel S Antonarakis and Changxue Lu and Brandon Luber and Huaizhang Wang and Yan Chen and Yezi Zhu and John L. Silberstein and Maritza N. Taylor and Benjamin L. Maughan and Channing J Paller and Samuel R Denmeade and Kenneth J. Pienta and Michael Anthony Carducci and Mario A. Eisenberger and Jun Luo},
  year={2016}
}

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Neue Therapieoptionen beim mCRPC

VIEW 1 EXCERPT
CITES BACKGROUND

Circulating tumor cells in prostate cancer: beyond enumeration.

Jie-Fu Chen, Yi-Tsung Lu, +3 authors Edwin M Posadas
  • Clinical advances in hematology & oncology : H&O
  • 2017

Applications of circulating tumor cells for prostate cancer

  • Asian journal of urology
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND

Similar Papers